Spesolimab for a child with generalized pustular psoriasis accompanied epilepsy and hyperactivity

Area of Science:

• Dermatology
• Genetics
• Pediatrics

Background:

• Generalized Pustular Psoriasis (GPP) is a rare, severe skin condition.
• Pediatric GPP cases are challenging to treat, especially when refractory.
• Genetic mutations in IL36RN can contribute to GPP pathogenesis.

Purpose of the Study:

• To evaluate the efficacy and safety of spesolimab for treating pediatric GPP.
• To assess the treatment response in a young patient with refractory GPP and comorbidities.

Main Methods:

• Case report of a 10-year-old male with refractory GPP.
• Genetic analysis revealed IL36RN mutations (c.115+6T>C homozygous and c.227C>T heterozygous).
• Treatment with spesolimab was administered.

Main Results:

• Spesolimab treatment led to a complete and rapid response in the pediatric GPP patient.
• Pustules, erythema, and scaling resolved within one week of treatment initiation.
• The patient tolerated spesolimab well, showing significant clinical improvement.

Conclusions:

• Spesolimab demonstrates significant therapeutic efficacy in pediatric GPP.
• It represents a promising future treatment strategy for pediatric GPP.
• Targeting IL-36 signaling pathway is effective for GPP management.